Intensified adjuvant IFADIC chemotherapy for adult soft tissue sarcoma: A prospective randomized feasibility trial

Sarcoma

Volumn 4, Issue 4, 2000, Pages 151-160

  Brodowicz, Thomas ^a   Schwameis, Eva ^b   Widder, Joachim ^b   Amann, Gabriele ^c   Wiltschke, Christoph ^a   Dominkus, Martin ^b   Windhager, Reinhard ^b   Ritschl, Peter ^d   Pötter, Richard ^b   Kotz, Rainer ^b   Zielinski, Christoph C ^a,e  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Department of Orthopedic Surgery ^*  (Austria)

^c UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

^d ORTHOPAEDIC HOSPITAL SPEISING   (Austria)

^e UNIVERSITY OF VIENNA   (Austria)

Author keywords

Adjuvant; Chemotherapy; Radiotherapy; Sarcoma; Soft tissue

Indexed keywords

DACARBAZINE; DOXORUBICIN; IFOSFAMIDE;

ADULT; AGED; ALOPECIA; ARTICLE; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DESQUAMATION; DOSE RESPONSE; DRUG MIXTURE; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; FEMALE; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; RANDOMIZED CONTROLLED TRIAL; SOFT TISSUE SARCOMA; STOMATITIS; THROMBOCYTOPENIA; TUMOR RECURRENCE;

EID: 0034527930     PISSN: 1357714X     EISSN: None     Source Type: Journal    
DOI: 10.1155/2000/126837     Document Type: Article

References (43)

1. Soft tissue sarcoma. Epidemiology and prognosis in 508 patients
2. Adjuvant chemotherapy in the treatment of soft-tissue sarcoma
3. Adjuvant therapy for sarcomas
4. Surgical margin in soft tissue sarcoma. The Scandinavian Sarcoma Group experience
5. Radiotherapy for soft tissue sarcoma
6. Treatment of the patient with stage M0 soft tissue sarcoma
7. The George Edelstyn Memorial Lecture. Radiation in the management of malignant soft tissue tumours
8. Radiation therapy in Ewing's sarcoma: An update of the CESS 86 trial
9. Sarcomas of soft tissues
10. A randomized trial for the treatment of high-grade soft-tissue sarcomas of the extremities: Preliminary observations
11. Late results of a randomized trial for the treatment of soft tissue sarcomas of the extremities in adult patients
12. Adjuvant chemotherapy with CYVADIC in high-risk soft tissue sarcoma: A randomized prospective trial
13. Preliminary results of an adjuvant randomized trial on high risk extremity soft tissue sarcomas. The interim analysis
14. Adjuvant CYVADIC chemotherapy for adult soft tissue sarcomareduced local recurrence but no improvement in survival: A study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group
15. Adjuvant chemotherapy for patients with high-grade soft-tissue sarcomas of the extremities
16. The importance of combination chemotherapy for adjuvant treatment of high-risk patients with soft-tissue sarcomas of the extremities
17. Lancet
18. Cyclophosphamide, vincristine, adriamycin and DTIC (CYVADIC) combination chemotherapy for the treatment of advanced sarcomas
19. Chemotherapy of advanced soft-tissue sarcomas
20. Response to mesna, doxorubicin, ifosfamide and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy
21. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas
22. Dose: A critical factor in cancer chemotherapy
23. Clinical impact of chemotherapy dose escalation in patients with hematologic malignancies and solid tumors
24. Dose intensive therapy does improve response rates - Updated results of studies of adriamycin and ifosfamide with growth factors in patients with untreated soft tissue sarcomas
25. Effect of high dose ifosfamide in advanced soft tissue sarcomas. A multicenter phase II study of the EORTC soft tissue and bone sarcoma group
26. High dose therapy in germ cell tumors: When, what, and how much?
27. Staging of musculoskeletal neoplasms
28. Muskuloskeletal Tumor Surgery
29. Soft Tissue Tumors 3rd edition
30. Diagnostic Histopathology of Tumors 1st edition
31. Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the European Organization for Research and Treatment of Cancer/Soft Tisue and Bone Sarcoma Group
32. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas
33. Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: An analysis of 2,185 patients treated with anthracycline-containing first-line regimens a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study
34. Adjuvant chemotherapy with doxorubicine in high-grade soft tissue sarcoma: A randomized trial of the Scandinavian Sarcoma Group
35. Pooled results from three randomized adjuvant studies of doxorubicin versus observation in soft tissue sarcoma: 10 year results and review of the literature
36. A randomized prospective trial using postoperative adjuvant chemotherapy (adriamycin) in high-grade extremity soft tissue sarcoma
37. Randomized study of systemic chemotherapy following complete excision of nonosseous sarcomas
38. A randomized clinical trial of adjuvant adriamycin in uterine sarcomas: A gynecologic oncology group study
39. Granulocyte-macrophage colony-stimulating factor allows safe escalation of dose-intensity of chemotherapy in metastatic adult soft tissue sarcomas: A study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group
40. Single-agent ifosfamide studies in sarcomas of soft tissue and bone: The MD Anderson experience
41. Dose response evaluation of adriamycin in human neoplasia
42. Dose-response is alive and well
43. Efficacy of lenograstim on hematologic tolerance to MAID chemotherapy in patients with advanced soft tissue sarcoma and consequences on treatment dose-intensity